Overview

Evaluation of Immediate Release Tablet

Status:
Completed

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

Single dose comparison of liquid and solid formulation, followed by study of effect of high fat breakfast. Evaluation of multiple dose pharmacokinetics and tolerability

Phase:

Phase 1

Details

Lead Sponsor:

F2G Biotech GmbH
F2G Ltd.

Collaborator:

Quotient Clinical

Treatments:

Olorofim